Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 3/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | PDE1A | P54750 | 5/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 5/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 5/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30542377 | 1.00 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL31127844 | 1.00 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL30542415 | 1.00 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL31642882 | 1.00 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL31643015 | 1.00 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL24535801 | 1.00 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL31127821 | 1.00 | RXRA (0.37) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL31527282 | 0.89 | RXRA (0.37) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL25375066 | 0.88 | CYP4F2 (0.40) | RXRARXRBRXRGATRCYP4F2 | |
| SCHEMBL30542431 | 0.88 | CYP4F2 (0.40) | RXRARXRBRXRGATRCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688788-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | PFIZER INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250034173-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2025-01-30 | — | — | US | disclosed |
| WO-2024209339-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | PFIZER INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240336631-A1 | Pyrido[4,3-d]pyrimidine Compounds | PFIZER INC. (US) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336631-A1 | Pyrido[4,3-d]pyrimidine Compounds | DPYD, PNPO, TYMP | RXRA 1274/4885RXRB 1070/4885RXRG 1502/4885 |
| US-12281127-B2 | Pyrido[4,3-d]pyrimidine compounds | DPYD, PNPO, TYMP | RXRA 1274/4885RXRB 1070/4885RXRG 1502/4885 |
| US-20250034173-A1 | PYRIDO[4,3-D]PYRIMIDINE COMPOUNDS | DPYD, PNPO, TYMP | RXRA 1274/4885RXRB 1070/4885RXRG 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.